Yes. The DRS-R98 diagnostic items—temporal onset, perceptual abnormality characteristics, and physical disorder evidence—help distinguish delirium (acute, fluctuating, with identifiable cause) from chronic dementia. Studies show DRS-R98 total scores above 18 have high specificity for delirium versus dementia when clinical context is considered.

Reliable DRS-R98 use requires training in the standardized administration interview and the item anchor descriptors in the scale manual. Published inter-rater reliability (ICC) is typically above 0.90 in trained raters. Brief clinical use without training risks significant scoring inconsistency.

For research applications, DRS-R98 is typically repeated every 24-48 hours. In clinical practice, daily assessment during the acute phase of delirium is appropriate. Once scores fall below the threshold and remain stable for 48 hours, delirium can be considered resolved.

Yes. DRS-R98 has been used in palliative populations to characterize terminal delirium severity and guide pharmacological management. The structured item set helps document symptom burden for families and care teams in a way that supports difficult conversations about prognosis.

Both DRS-R98 and the Memorial Delirium Assessment Scale (MDAS) are validated delirium severity instruments. DRS-R98 has a more comprehensive item set including diagnostic items and better distinguishes delirium from dementia. MDAS is shorter (10 items, 0-30 scale) and may be preferred in oncology or palliative settings.